CureMetrix Company Profile

Background

Founded in 2014, CureMetrix is a privately held company headquartered in San Diego, California. The company is dedicated to advancing technology that enhances disease detection and improves cancer survival rates globally. By leveraging artificial intelligence (AI) and deep learning, CureMetrix develops next-generation medical image analysis tools that radiologists and patients can trust. Their mission is to save lives by providing radiologists with advanced technology to support mammogram evaluations, leading to improved clinical outcomes, reduced healthcare costs, and increased patient assurance.

Key Strategic Focus

CureMetrix focuses on developing AI-based solutions for mammography, aiming to improve the accuracy of detecting and classifying anomalies in breast cancer screenings. Their core products include:

cmTriage®: The first FDA-cleared AI-based triage software in the U.S. for mammography, enabling radiologists to prioritize their worklists based on suspicious cases requiring immediate attention.

cmAssist®: An investigational AI-based computer-aided detection (CAD) algorithm that identifies, marks, and quantifies suspicious lesions in mammograms.

cmAngio®: An AI-based software that detects and localizes Breast Arterial Calcifications (BAC) in mammograms, aiding in the assessment of cardiovascular risk.

These technologies are designed to support radiologists in improving clinical and operational outcomes while reducing the overall cost of providing screening services.

Financials and Funding

CureMetrix has raised a total of $28.2 million in funding over multiple rounds. Notable investors include Analytics Ventures and XB Ventures. The funds have been utilized to advance their AI-based medical imaging technologies and expand their market presence.

Technological Platform and Innovation

CureMetrix's proprietary technologies leverage AI and deep learning to enhance medical image analysis:

cmTriage®: Utilizes AI to prioritize mammography worklists, allowing radiologists to focus on cases that require immediate attention.

cmAssist®: Employs deep learning algorithms to identify and mark suspicious lesions, providing a neuScore™ that indicates the level of suspicion.

cmAngio®: Analyzes mammograms to detect Breast Arterial Calcifications, offering insights into a patient's cardiovascular health.

These innovations aim to improve the accuracy and efficiency of breast cancer detection and cardiovascular risk assessment.

Leadership Team

Navid Alipour: Co-Founder and CEO, overseeing the company's strategic direction and growth.

Kevin Harris: Co-Founder and President, responsible for leading the company's operations and business development.

Lisa Watanabe, MD: Chief Medical Officer, providing medical oversight and guidance for product development.

Sam Dribin: Chief Technology Officer, leading the technological development and innovation efforts.

Tom Saftig: Chief Financial Officer, managing the company's financial strategy and operations.

Competitor Profile

Market Insights and Dynamics

The AI-based medical imaging market is experiencing significant growth, driven by the increasing demand for advanced diagnostic tools and the integration of AI in healthcare. The focus on improving early detection and reducing false positives in medical imaging is a key driver in this sector.

Competitor Analysis

CureMetrix operates in a competitive landscape with several notable companies:

Poxel: A research-integrated pharmaceutical company developing products for metabolic diseases.

MV Sistemas: A Brazilian provider of core technology management systems for healthcare.

iMDSoft: A provider of clinical information systems for critical, perioperative, and acute care environments.

MEDIAN Technologies: Develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice.

These competitors focus on various aspects of healthcare technology, from pharmaceutical development to clinical information systems and oncology imaging solutions.

Strategic Collaborations and Partnerships

CureMetrix has established significant partnerships to enhance its market position and technological capabilities:

Volpara Health x Lunit: In February 2025, CureMetrix entered into an agreement with Volpara Health, a Lunit company, to expand access to cmAngio®. This partnership enables over 3,500 facilities using Volpara Health software to integrate cmAngio® into their services.

Rezolut, LLC: In August 2021, CureMetrix launched a pilot program with Rezolut, a national diagnostic medical imaging services provider, aiming to improve breast cancer detection through advanced AI technology.

These collaborations aim to enhance the adoption of AI-driven solutions in medical imaging, improving patient outcomes and operational efficiency.

Strategic Opportunities and Future Directions

CureMetrix is poised to expand its AI-based solutions beyond mammography, exploring applications in other areas of medical imaging and disease detection. The company's focus on continuous innovation and strategic partnerships positions it to capitalize on the growing demand for AI in healthcare, aiming to improve diagnostic accuracy and patient care across various medical fields.